November 30, 2016 - By Adrian Mccoy · 0 Comments
The stock of CANTABIO PHARMACEUTICALS INCORPORATED (OTCMKTS:CTBO) registered a decrease of 7.26% in short interest. CTBO’s total short interest was 11,500 shares in November as published by FINRA. Its down 7.26% from 12,400 shares, reported previously. With 37,800 shares average volume, it will take short sellers 0 days to cover their CTBO’s short positions. About 2,740 shares traded hands. Cantabio Pharmaceuticals Inc (OTCMKTS:CTBO) has risen 6.00% since October 31, 2016 and is uptrending. It has outperformed by 0.77% the S&P500.
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology firm focusing on commercializing therapies and the intellectual property generated from its research and development activities for Parkinson’s disease , Alzheimer’s disease (AD) and other related neurodegenerative diseases. The company has a market cap of $7.90 million. The Company’s strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into a drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. It currently has negative earnings.
More recent Cantabio Pharmaceuticals Inc (OTCMKTS:CTBO) news were published by: Seekingalpha.com which released: “Cantabio Pharma: Is This Stock Worth Remembering?” on June 13, 2016. Also Globenewswire.com published the news titled: “Cantabio Pharmaceuticals to Present at 2016 Silicon Valley Bank Healthcare …” on September 19, 2016. Globenewswire.com‘s news article titled: “CANTABio and Gardedam Therapeutics complete Merger to Tackle Development of …” with publication date: December 21, 2015 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy